LivaNova(US:LIVN)2021-02-26 13:58Financial Performance - Q4 2020 - Net sales decreased by 7.7% to $270 million[15] - Cardiovascular sales decreased by 10.1% to $159.6 million[22] - Cardiopulmonary sales decreased by 10.0%[22] - Heart Valves sales decreased significantly by 27.2%[22] - Advanced Circulatory Support sales increased significantly by 50.3%[22] - Neuromodulation sales decreased by 3.8%[23] - Adjusted segment operating income was $48.6 million, representing 18.0% of sales[24] - Adjusted diluted EPS was $0.71[44] Financial Performance - Full Year 2020 - Net sales decreased by 13.7% to $934 million[18] - Adjusted diluted EPS was $3.79[65] 2021 Guidance - Worldwide net sales growth is projected to be between 8% and 13%[74] - Diluted EPS is projected to be between $1.40 and $1.90[74] - Free Cash Flow (excluding extraordinary items) is projected to be between $30 million and $50 million[74]